Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Nuscale Power Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Nuscale Power Corporation trades at $8.6 (market cap $2.98B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.7× Nuscale Power Corporation's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| BIO | SMR | |
|---|---|---|
Market Cap | $8.04B | $2.98B |
Sector | Health | Utilities |
52-Week High | $339.75 | $53.43 |
52-Week Low | $241.71 | $8.36 |
Enterprise Value | $7.85B | $2.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
NuScale Power (SMR) trades at $8.36, down 7.42% in the last session and near its 52-week low. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal significant challenges including negative net income margins (-2,066.55%) and declining revenue projections. Recent news highlights the company's unique position as the only US company with certified small modular reactor design approval, though commercialization timelines remain uncertain.
Despite analyst consensus pointing to 46% upside potential with a $12.25 price target, SMR faces substantial execution risks. The company must demonstrate commercial viability of its reactor technology while managing cash burn. Long-term potential exists in nuclear energy's AI-driven demand surge, but near-term profitability remains elusive with projected losses through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
